Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
KVISTGAARD, Denmark, May 29, 2013 - Bavarian Nordic A/S (OMX: BAVA) announced today that promising data from a Phase 2 trial of its CV-301 cancer immunotherapy candidate in patients with resected metastatic colorectal cancer were recently published in the Annals of Surgery. In a study conducted at Duke University, 74 patients who were disease free after surgical resection of metastatic colon cancer received chemotherapy followed by immunotherapy with CV-301 (formerly designated as PANVAC-VF) either as CV-301 modified dendritic cells or in combination with GM-CSF. Compared to a group of contemporary control patients who were matched for key clinical features and had similar surgery and chemotherapy, the overall survival of the CV-301 treated patients was significantly longer (p < 0.0001). Treatment with CV-301 was well tolerated, with injection site reactions, fever, fatigue and muscle soreness as the most common side effects.
Help employers find you! Check out all the jobs and post your resume.
